Dear Colleagues:
Welcome to the November issue of Innovations in Clinical Neuroscience.
In this month’s installment of “The Interface,” Sansone and Sansone review agomelatine, a novel antidepressant currently seeking approval in the United states for treatment of depression.
Next, Jadhav et al review the literature on the effects that unexpected death, including suicide, of child or adolescent patients might have on child and adolescent psychiatry (CAP) trainees in this month’s “Psychotherapy Rounds.” CAP trainees may find themselves dealing with the academic, personal, administrative, and legal consequences of this unfortunate but unavoidable event. The authors make recommendations for training programs to better prepare CAP trainees for the possibility of unexpected death in their child and adolescent patients.
Following this, Khawaja et al provide an overview of the declining role of the psychiatrist in group psychotherapy. They include results of a survey conducted by their group. The authors opine on the causes for this decline and why group therapy training is important for psychiatry residents. The authors also provide several recommendations to encourage the inclusion of group psychotherapy training in residency programs.
Next, Jadresic et al share the results of their prospective, observational, open-label, clinical study that compared endoscopic thoracic sympathectomy for blushing with generalized social anxiety disorder versus sertraline treatment and no treatment. The authors found that endoscopic thoracic sympathectomy was associated with a greater reduction of blushing and Brief Social Phobia Scale scores and higher degrees of satisfaction with treatment, in comparison to sertraline and no treatment.
Finally, Meymandi describes how biology carries the promise of reinvigorating the psychoanalytic exploration of mind in this month’s Meymandi at Large.
We hope you enjoy the issue.
Sincerely,
Amir Kalali, MD
Editor, Innovations in Clinical Neuroscience
